Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion (ESPR – Research Report) and keeping the price target at $16.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Joseph Pantginis has given his Buy rating due to a combination of factors related to the promising clinical outcomes of Esperion’s bempedoic acid (BDA) in high-risk cardiovascular populations. In particular, the recent analyses from the CLEAR Outcomes Trial revealed that BDA significantly benefits obese patients who are at high cardiovascular risk. The study showed a meaningful reduction in LDL-C and hs-CRP levels, which are key markers of cardiovascular health.
Moreover, the trial indicated a substantial decrease in major adverse cardiovascular events among those treated with BDA compared to the placebo group, with a notable 23% risk reduction in the primary endpoint. The safety profile of BDA was consistent with previous findings, making it a compelling option for patients with obesity or conditions such as peripheral artery disease or liver steatosis. Pantginis anticipates that these results will enhance the clinical adoption of BDA and support its expansion as a preferred therapy for managing lipid levels and cardiovascular risk globally.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.